Small Cap Feast

Small Cap Feast – 29 January 2020

Set Menu AIM:

Total number of AIM Companies (Incl Susp):

Total number of AIM Companies trading: *
* As at

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): *

Total number of NEX Growth Market Companies trading: *
* As at

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): *

Total number of Standard List Companies trading: *
* As at

Dish of the Day:

No Joiners Today

 

Off the Menu:

No Leavers Today

 

Dish of the Day:

Off the Menu:

What’s Cooking in the IPO Kitchen?

AIM

Intention to float by Gemfields Group. No Capital Raise. Currently listed on JSE. (GML:JNB) at circa £122m.  The Group’s key producing assets, the Kagem emerald mine in Zambia  (believed to be the world’s single largest producing emerald mine) and the Montepuez ruby mine in Mozambique (one of the most significant recently discovered ruby deposits in the world), are both expected to have long mine-lives with potential for expansion. Also owns the  Faberge brand. Due Valentines Day 2020.

Main Market (Standard List)

The Proof Of Trust has announced its intention to list on the Standard Market.  The Blockchain based business, owns patents to a protocol which facilitates dispute resolution based upon smart contract disputes.  Transaction details TBC.

Main Market (Premium)

Cabot Square—Closed ended investment fund focussed on alternative assets and asset manager. Looking to raise £200m.  Will target investment opportunities that are expected to generate an attractive risk adjusted return and that can also make a positive ESG impact by focusing on some of the biggest challenges facing societies and economies.  Due 14 Feb.

Calisen Group. Potential Intention to Float. Owner and manager of essential energy infrastructure assets through its subsidiaries Calvin Capital and Lowri Beck . Consolidated FY Dec 18 revenue £162.1m and operating profit £25.4m. Raising up to £300m in primary plus partial vendor sale.  Expected Admission February 2020

The Global Sustainable Farmland Income Trust will invest in a diversified portfolio of operational farmland assets located in major agricultural markets including the United States, Europe, New Zealand, Australia and certain countries within Latin and South America. Raising up to $300m.   Due 28 February.

Main Market (Specialist Funds)

Investment firm Nippon Active Value fund is seeking to raise up to £200m at an issue price of 100p per share via an IPO.   The company aims to invest in a portfolio of quoted Japanese stocks with market capitalisations of up to $1bn.   First day of dealings expected early February.

 

Breakfast Buffet

Thor Mining* (THR.L) 0.375p £4m

Maiden mineral resource estimates for the White Violet and Samarkand tungsten and copper deposits at Bonya (Thor 40%). Highlights:

White Violet—Inferred Resources of 495,000 tonnes, grading 0.22% Tungsten Trioxide (WO₃) and 0.06% copper (Cu), containing 1,090 tonnes of WO₃, and 300 tonnes Cu.

Samarkand—Inferred Resources of 245,000 tonnes, grading 0.19% Tungsten Trioxide (WO₃) and 0.13 % copper (Cu), containing 465 tonnes of WO₃, and 320 tonnes Cu.

Both deposits outcrop and remain open at depth, while Samarkand, in particular, shows potential for strike extension to the copper mineralisation.

Each deposit considered amenable to open cut extraction for significant components of the resource.

Both deposits situated in close proximity to the Thor Mining Molyhil tungsten and molybdenum project, and potentially therefore within economic trucking distance.

The Bonya project hosts additional known tungsten and copper deposits, and some high tenor copper strike extension at Samarkand.  These will be tested in due course.

 

Concepta (CPT.L) 1.3p £3.4m

Update from the UK’s most accurate home-use fertility tracking and pregnancy testing system .

A newly upgraded commercial website has been launched (www.mylotus.com) and this will be followed by a fully optimized website launch and cross-channel marketing strategy launched before the end of the first half 2020.

In addition, the Company expects to launch a modest clinical trial with a leading London hospital in Q1 2020, to further highlight the accuracy of myLotus® when measured against in-clinic processes, and demonstrate the value of this product to the patient. The new management team has identified a number of cost reduction opportunities and has already achieved a 30% cost reduction to the current operating overhead, the impact of which will be seen in the financial year ending December 2020

A substantial portfolio product development programme is now underway  with new products expected to be ready for commercialisation in the next 12 months.

 

Ergomed (ERGO.L) 439p £210m

The company focused on providing specialised services to the pharmaceutical industry, announces a trading update for the year ended 31 December 2019.

Following the positive results for the first half of the year reported in September 2019, Ergomed continued to deliver strong year on year top-line growth and financial performance across the business and expects revenue for the year ended 31 December 2019 to be in line with current market expectations and EBITDA for the year ended 31 December 2019 to be ahead of current market expectations.

Revenues for 2019 are expected to be in line with expectations at approximately £68m, an increase of 26% over prior year (2018: £54.1m), with CRO revenues increasing 23% from £26.6m to £32.6m and PV revenues increasing 29% from £27.5m to £35.4m.  The combined CRO and PV order book at the end of 2019 is expected to be approximately £125m, up by 15% over prior year (2018: £109m). The Company continued to be debt-free at the year end with cash and equivalent balances over £14m (2018: £5.2m).

 

Fusion Antibodies (FAB.L) 92p £20.3m

The specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, provides an update on current trading.  Q3 trading has continued the favourable trends experienced in  H1. Expects revenues for the year ended 31 March 2020 to be significantly ahead of current market expectations, and materially ahead of the previous year (FY2019: £2.2m).

Gross profit margin remains ahead of the previous financial year. The revenue growth is largely a result of an increase in sales of existing services, as the contribution from newer high margin services has yet to be fully achieved to the extent previously anticipated. Accordingly, the Company expects gross profit margin for the current financial year to be marginally below current market expectations but ahead of FY2019. The Company continues to invest in the development of new services, whilst maintaining EBITDA and a cash position broadly in line with current market expectations for the full year. 

 

EKF Diagnostics (EKF.L) 33.8p £153.4m

FYDec19 update.  The Company confirms that revenues and adjusted EBITDA are in line with market expectations, which have already been upgraded following previous trading updates, as announced on 6 November 2019. Cash generation during the period was strong, with net cash at year-end of £11.4m, after the payment of performance bonuses  

Renalytix AI plc (AIM: RENX), the spin out from EKF which floated in November 2018, has continued to perform well. As at 31 December 2019, EKF held marketable securities (2,677,981 RENX shares) at approximately £9.17m at fair value (compared to book value at cost of investment of £3.24m).

 2019 has seen the Company continue its momentum by delivering on its strategic goals and the Board is confident that this progress will continue into 2020.  Further upside is expected from the OEM contract with McKesson-Surgical Inc. for the distribution of Diaspect Tm in the US and the enzyme manufacturing business with Oragenics, Inc.

 

Fulcrum Utility Services (FCRM.L) 24.25p £53.9m

The independent multi-utility infrastructure and services provider, announces the appointment of Daren Harris as Chief Executive Officer with immediate effect.

The Group also announces the appointment of Terry Dugdale, Chief Operating Officer (Gas), to Group Chief Operating Officer and to the Board as an executive director with immediate effect.

Daren joined the Company and its Board as Chief Financial Officer on 24 June 2019, bringing significant experience gained in various senior and Board level roles in the construction, contracting, electrical engineering and energy services sectors.  Prior to joining the Group, he was Group Finance Director of The Byrne Group, a construction services provider which during his tenure achieved turnover in excess of £300m and Group Finance Director of NG Bailey, a £400m turnover engineering and services business.

 

Empresaria Group (EMR.L) 52.5p £25.7m

The global specialist staffing group, today provides a trading update for the financial year ended 31 December 2019 ahead of announcing its full year results on Wednesday 18 March 2020.

 The Board confirms that it expects the Group to deliver results in line with current market expectations for the financial year ended 31 December 2019.

 Net fee income has grown 3% from the prior year, 2% in constant currency.  As expected, net fee income progress was weighted towards the first half of the year with the second half flat year on year.  The growth in businesses such as in our Offshore Recruitment Services sector, which has had another very strong year, has been offset by the impact of the previously communicated challenges in UK Engineering, the weakness in the German automotive sector and Brexit.

“While we invest in positioning the business for future growth in net fee income and profitability, our diversity across sectors and geographies continues to provide a strong, profitable and cash generative foundation from which to build.”

 

Windar Photonics (WPHO.L) 30p £14.9m

 The technology group that has developed a cost efficient and innovative LiDAR wind sensor for use on electricity generating wind turbines, has been granted 0.24m in development funding from the Eurostars for the LAWIS project. The total project grants amount to 0.7m and includes the Technical University of Denmark and an optical manufacturer in Lithuania.

The aim of the granted project is to develop and demonstrate a one-unit LiDAR solution that combines the optical LiDAR head with the control unit and at the same time offer cost reductions and technological benefits.

 Martin Rambusch, General Manager of the Company, commented: “I am very pleased that Windar’s participation in this development project is alongside strong partners within the industry. The development and demonstration of the one-unit LiDAR solution will benefit our global customers as we are able to optimize our LiDAR offering even further, and at the same time add more features to our already developed LiDAR solutions.

 

Polarean Imaging (POLX.L) 33p £37.8m

Positive results from pivotal Phase III Clinical Trial. Both trials met their primary endpoint, showing pre-defined equivalence of hyperpolarized 129Xenon Gas MRI to an approved comparator, 133 Xenon Scintigraphy. Company plans for NDA submission to FDA in Q3 2020. Polarean’s technology could offer clinicians a powerful tool to visualise lung function, overcoming limitations of existing methods of diagnosis and monitoring treatment.

 

Oakley Capital (OCI.L) 269.5p £535m

 Highlights for the year

  • Net Asset Value (“NAV”) per share of 345 pence and NAV of £686m
  • Total NAV return of 25%
  • Total shareholder return of 56%
  • OCI invested £103m and received proceeds of £78m
  • Buy-back and cancellation of 6m shares

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.